ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Daiichi Sankyo and Nichi-Iko to develop COVID-19 inhalation drug

Japanese companies see the method as a more effective coronavirus treatment

Japanese pharmaceutical companies Daiichi Sankyo and Nichi-Iko are launching a project to develop a potential inhalation treatment for the coronavirus.

TOKYO -- Japanese pharmaceutical companies Daiichi Sankyo and Nichi-Iko, in cooperation with the University of Tokyo, will work to develop a potential inhalation treatment for the coronavirus, the parties announced Monday.

The project will focus on turning Nichi-Iko's protease inhibitor Futhan, a candidate treatment for COVID-19, into an inhalation preparation to make it more effective.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more